Here we demonstrate that influenza virus replication, host responses to infection, evolution through mutation or gene reassortment, and clinical efficacy of antiviral drugs can be reconstituted in a human Airway Chip microfluidic culture device. Modeling human-to-human transmission of infection in the continued presence of antiviral drugs on chips led to the 20 emergence of clinically prevalent mutations responsible for amantadine-and oseltamivirresistance, as well as the discovery of new resistance mutations. Analysis of infection responses resulted in identification of host therapeutic targets and demonstration that existing non-antiviral
2 drugs may be repurposed to inhibit viral replication and synergize with antiviral therapeutics by targeting the host response to infection rather than the virus itself. This Influenza Chip may 25 represent an alternative preclinical tool for development of new antiviral drugs and vaccines.
Main Text:
The greatest challenge for combating influenza virus infection is rapid virus evolution among human populations, which leads to the emergence of mutated viruses making existing anti-influenza drugs and vaccines ineffective (1, 2) . Development of more effective means to 30 control influenza will therefore require better prediction of virus evolution of resistance to therapy and more rapid development of novel drugs and vaccines, both of which are currently limited by the lack of clinically relevant preclinical models (3). Here we explored whether human Organ-on-a-Chip (Organ Chip) microfluidic culture technology (4-7) can be used to develop a physiologically and clinically relevant in vitro model of human influenza A infection 35 for prediction of influenza evolution and preclinical evaluation of anti-influenza therapeutics.
Using a previous protocol with some modification (5) , we first built a human lung Airway Chip containing 2 parallel microchannels separated by an extracellular matrix (ECM)coated membrane lined by primary human lung airway epithelial cells (HLAECs) cultured under an air-liquid interface (ALI) on one side within the 'airway' channel, with human pulmonary 40 microvascular endothelial cells (HPMVECs) grown on the other in the presence of continuous medium flow to mimic vascular perfusion with or without human immune cells within the 'vascular' channel ( Fig. 1A) . S1E ). Under these microfluidic culture conditions, these highly differentiated human airway structures and functions can be maintained for more than 2 months in vitro.
We then inoculated the airway epithelium with GFP-labeled influenza H1N1 (PR8) virus 55 (11) through the upper air channel of the microfluidic chip to mimic in vivo infection with airborne influenza (Fig. 1A) . Real-time fluorescence microscopic analysis confirmed viral infection of the human airway epithelium as indicated by GFP expression ( Fig. 1B and movie S1), and this was accompanied by damage to the epithelium, including disruption of tight junctions, loss of apical cilia, and compromised barrier function ( Fig. 1B,C) . Influenza infection 60 also led to disruption of the endothelium as evidenced by loss of VE-cadherin containing adherens junctions ( Fig. 1B) , which was consistent with vascular leakage that is induced by influenza infections in vivo (12, 13) . Analysis on replication kinetics of H1N1 and H3N2 viruses indicated that both viruses exhibited large (10,000-to 100,000-fold) increases in viral titers over 24 to 48 hours; however, H3N2 exhibited ~10-fold greater replication efficiency ( Fig. 1D ) and 65 caused more barrier function damage and cilia loss (Fig. 1C,E) , which is consistent with the clinical observations that H3N2 is more infectious and causes more severe clinical symptoms in humans (14) . Assessment of innate immune responses to infection of H1N1, H3N2 and H5N1 revealed that H3N2 and H5N1 viruses that produce more severe clinical symptoms than H1N1 4 induced higher levels of cytokines and chemokines, and the most virulent H5N1 induced the 70 highest concentrations ( fig. S2) . These results mirror the clinical finding that patients infected with H5N1 have increased serum concentrations of these inflammatory factors relative to those with H1N1 or H3N2, which significantly contributes to disease pathogenesis (14) . Importantly, donor-to-donor variability was minimal as similar results were obtained among chips created with HLAECs obtained from 5 different donors. 75 We next tested the potential of our human Airway Chip influenza model to enable the in vitro prediction of influenza virus evolution by mutation when viruses spread from patient-topatient through human populations. Human patient-to-patient transmission of influenza virus was mimicked by passaging virus from chip to chip under the selection pressure of antiviral drugs ( Fig. 2A) . When we treated human airway chips infected with influenza A/WSN/33 (H1N1) 80 virus with the clinically used anti-influenza drug, amantadine, at a dose (1 µM) that inhibits replication of this influenza strain by ~90%, its inhibition rate decreased to ~10% after 8 human chip-to-chip passages ( Fig. 2A,B) , indicating the emergence of a pool of amantadine-resistant viruses. Sequencing of these drug-resistant viruses led to the identification of 3 mutated virus strains with mutation sites located within the viral M2 protein ( Fig. 2C) , which is the known 85 target of amantadine (15) . Among them, a single mutation at S31N conferred amantadineresistance with the half inhibitory concentration (IC50) increasing over 500-fold (from 47 nM to 24.7 µM) ( Fig. 2D) . Importantly, this is the same site mutation that has been frequently detected in clinically validated amantadine-resistant influenza viruses (16) . In addition, we identified two previously unknown double mutants containing the S31N mutation, as well as either G34E or 90 L46P substitutions ( Fig. 2C) . Interestingly, these mutations conferred even greater resistance to amantadine with the IC50 increasing over 1000-fold (from 47 nM to > 100 or 65 µM, 5 respectively) ( Fig. 2D) , indicating that extended exposure to amantadine may induce the emergence of more highly resistant virus strains.
We used the same approach to explore the propensity of the widely used anti-influenza 95 drug, oseltamivir, to induce viral resistance, and found that the inhibition rate also decreased significantly (from ~90% to ~30%) over time ( Fig. 2E) . But this was a much slower process as 25 human chip-to-chip passages were required for resistance to develop ( Fig. 2E) . Sequencing of the oseltamivir-resistant virus pool revealed one strain with a mutation site located within the influenza viral neuraminidase (NA) protein that is the known target of oseltamivir ( Fig. 2F) (17). 100 The H274Y mutation conferred oseltamivir resistance with the IC50 increasing from 58 nM to 2.67 µM (Fig. 2G) , and importantly again, the same mutation has been detected in clinical cases (17).
To explore whether the Airway Chip also could support influenza virus evolution through gene reassortment as occurs when different virus strains co-infect the same host (18) , 105 chips were co-infected with H3N2 and H1N1 viruses and their progeny viruses were then isolated and sequenced (Fig. 3A) . Genotype analysis of 100 progeny viruses revealed that the H3N2 and H1N1 parental strains were predominant; however, 19 virus reassortants emerged that represented three distinct genotypes (3, 4, and 5) ( Fig. 3B) . These included seven H1N2 reassortants containing the hemagglutinin (HA) gene segment from H1N1 with the other gene 110 segments from H3N2 in genotype 3; two new H3N2 reassortants containing the polymerase basic protein-1 (PB1) gene segment from H1N1 with others from H3N2 in genotype 4; and ten new H3N2 reassortants containing the matrix protein (M) gene segment from H1N1 with others from H3N2 in genotype 5 (Fig. 3B) . These reassortants did not exhibit higher replication competence than their parental strains (Fig. 3C) , but the emergence of antigenically drifted 115 6 H1N2 reassortants led to complete resistance to H3N2-specific anti-HA antibody (Fig. 3D) ,
indicating the potential risk of pandemic development if antigen-mismatched vaccination occurred. Importantly, the H1N2 reassortant predicted on-chip also has been detected in patients during influenza season in which H1N1 and H3N2 co-circulated (18) . Even more concerning, a high frequency of double resistant viruses emerged that are resistant to both oseltamivir and 120 amantadine as a result of reassortment of oseltamivir-resistant virus and amantadine-resistant virus when they were used to co-infect human airway chips ( fig. S3) . Thus, in vivo virus evolution through reassortment can be easily studied in this in vitro human influenza infection model.
Next, we tested the reliability of our model to evaluate anti-influenza therapeutics using 125 oseltamivir and anti-HA antibody ( fig. S4) . As oseltamivir is normally metabolized to release its active metabolite, oseltamivir acid, by the liver in vivo, we introduced oseltamivir acid into the vascular channel of a human airway chip infected with H1N1 virus, mimicking its oral administration and distribution through the vasculature in flu patients. Oseltamivir efficiently inhibited viral replication ( fig. S4A) , protected barrier function of airway ( fig. S4B) , and 130 maintained epithelial tight junctions ( fig. S4C ) in chips infected with influenza. In addition, an anti-H1N1 HA antibody significantly inhibited virus propagation, and it exhibited more potency against H1N1 than H3N2, as expected due to differences in antigen epitopes (fig. S4D) .
The Airway Chip was then used to explore whether host serine proteases could serve as alternative targets for therapeutic intervention given their significantly elevated expression in 135 human airway ( fig. S1E) , and their critical roles in influenza virus propagation (8, 10). We screened a library of serine protease inhibitors, and found that aprotinin/Trasylol, leupeptin, AEBSF and the clinically used anticoagulant, nafamostat exhibited anti-influenza efficacies 7 against H1N1 and H3N2 on-chip ( Fig. 4A and fig. S5 ). Nafamostat protected airway barrier function ( Fig. 4B) and tight junction integrity (Fig. 4C) , and decreased production of cytokines 140 and chemokines (Fig. 4D) , when the Airway Chips were challenged with influenza. Analysis of nafamostat's mechanism of action revealed that it efficiently blocks the cleavage of influenza viral HA0 protein into HA1 and HA2 subunits mediated by serine proteases, including TMPRSS11D and TMPRSS2 ( Fig. 4E and fig. S6A to C) , a process that is essential for influenza virus infection (19, 20) . This mechanism was also shared by the other protease 145 inhibitors ( fig. S6D) .
Oseltamivir is usually recommended for clinical use within 2 days of influenza infection (21, 22) , and when we added this drug at different time points of influenza infection on-chip, it similarly was only effective when administered within 48 h post-infection (Fig. 4F) . Nafamostat exhibited a similar 48 h therapeutic window; however, when these two drugs were combined, 150 they exerted a more potent anti-influenza effect (Fig. 4F) . Most importantly, by combining nafamostat with oseltamivir, we were able to extend the therapeutic window from 48 h to 96 h ( Fig. 4F) . Furthermore, no viral resistance to nafamostat was detected even when virus infection was transmitted over 30 chip-to-chip passages in the presence of this drug ( Figs. 2A and 4G) , which is ascribed to the highly conserved nature of host targets. This is significantly different 155 from all current clinically used viral protein-targeting antiviral drugs, such as amantadine and oseltamivir, which induce rapid emergence of drug-resistant virus strains (Fig. 2) (16, 17) .
Our results show that the human Airway Chip can be used to create a physiologically and clinically relevant in vitro model of human influenza infection. This experimental platform could be used to predict potentially emerging viruses that become resistant to current anti-160 influenza drugs or vaccines, and hence, cause influenza pandemics. By combining the influenza 8 evolution prediction in Airway Chips with existing influenza surveillance approaches (18, (23) (24) (25) , it might be possible to establish public databases of influenza evolution in humans, which could lead to better selection of candidate viruses for vaccines and early detection of drugresistant viruses (26) . This model also may enable preclinical evaluation of new anti-influenza 165 therapeutics, leading to the identification of candidate anti-influenza drugs. It is important to note that the protease inhibitor drugs we identified to have antiviral activity have a novel mechanism of action in that they target the host, rather than the virus itself, and thus, increase host tolerance to infection. As some of these existing drugs have been approved by the FDA for other medical uses (27), they could be repurposed and moved rapidly to clinical testing as anti-influenza 170 therapeutics either alone or in combination with existing antiviral agents. 10 This work was supported by grants from NIH (NCATS 1-UG3-HL-141797-01) and DARPA Additional data are presented in the Supplementary Materials.
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